Skip to content
Alimta(pemetrexed)
Alimta, Armisarte, Pemfexy (pemetrexed) is a small molecule pharmaceutical. Pemetrexed was first approved as Alimta on 2004-02-04. It is used to treat mesothelial neoplasms and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat mesothelioma and non-small-cell lung carcinoma. The pharmaceutical is active against dihydrofolate reductase. In addition, it is known to target thymidylate synthase, proton-coupled folate transporter, and trifunctional purine biosynthetic protein adenosine-3.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Alimta, Pemfexy (generic drugs available since 2022-05-25)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pemetrexed
Tradename
Company
Number
Date
Products
PEMETREXEDAllerganN-208419 RX2020-08-21
3 products, RLD, RS
PEMFEXYEagle PharmaceuticalsN-209472 RX2020-02-08
1 products, RLD, RS
Pemetrexed disodium
Tradename
Company
Number
Date
Products
PEMETREXED DISODIUMACCORD HLTHCAREN-214408 RX2022-07-19
4 products, RLD, RS
PEMETREXED DISODIUMHospiraN-214218 RX2022-06-22
3 products, RLD, RS
ALIMTAEli LillyN-021462 RX2004-02-04
2 products, RLD, RS
PEMETREXED DISODIUMSandozN-214657 RX2022-05-26
3 products, RLD, RS
PEMETREXEDShilpa MedicareN-215179 RX2023-05-22
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
alimtaNew Drug Application2021-02-22
pemfexyNew Drug Application2022-01-20
pemrydi rtuNew Drug Application2023-02-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mesothelial neoplasms—D018301—
non-small-cell lung carcinoma—D002289—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pemetrexed, Pemfexy, Eagle Pharms
96049902035-10-28DP
Pemetrexed Disodium, Pemetrexed, Shilpa
111478172035-03-26DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BA: Folic acid analogs, antimetabolites
— L01BA04: Pemetrexed
HCPCS
Code
Description
J9304
Injection, pemetrexed (pemfexy), 10 mg
J9305
Injection, pemetrexed, not otherwise specified, 10 mg
Clinical
Clinical Trials
885 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289982891521017524
MesotheliomaD008654C45101552127
Adenocarcinoma of lungD00007719241522224
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.90228321—3118
NeoplasmsD009369C8067229——87
Malignant mesotheliomaD00008600212213—131
Head and neck neoplasmsD0062586102——17
Ovarian neoplasmsD010051EFO_0003893C56781——15
Small cell lung carcinomaD055752663——14
AdenocarcinomaD000230353——10
Brain neoplasmsD001932EFO_0003833C71161——8
Pancreatic neoplasmsD010190EFO_0003860C25521——8
Neoplasm metastasisD009362EFO_0009708341—18
Show 19 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50816———21
Colorectal neoplasmsD015179813———18
Urologic neoplasmsD014571C64-C6837———9
SarcomaD01250925———7
Squamous cell neoplasmsD01830743———6
Peritoneal neoplasmsD01053414———5
Endometrial neoplasmsD016889EFO_000423032———5
Renal cell carcinomaD00229212——14
Fallopian tube neoplasmsD00518522———4
MelanomaD00854532———4
Show 42 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD0647262————2
ChordomaD002817EFO_00003341————1
Non-hodgkin lymphomaD008228C85.91————1
ChondrosarcomaD0028131————1
Primary myelofibrosisD055728D47.41————1
Hodgkin diseaseD006689C811————1
Uveal neoplasmsD014604EFO_10012301————1
PharmacokineticsD0105991————1
Medical sociologyD0129621————1
LeukemiaD007938C951————1
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinomaD002294————11
Circulating neoplastic cellsD009360————11
Sensitivity and specificityD012680————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePEMETREXED
INNpemetrexed
Description
Pemetrexed, sold under the brand name Alimta among others, is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC)..
Classification
Small molecule
Drug classantineoplastic thymidylate synthetase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1
Identifiers
PDB3K2H
CAS-ID137281-23-3
RxCUI68446
ChEMBL IDCHEMBL225072
ChEBI ID63616
PubChem CID446556
DrugBankDB00642
UNII ID04Q9AIZ7NO (ChemIDplus, GSRS)
Target
Agency Approved
DHFR
DHFR
Organism
Homo sapiens
Gene name
DHFR
Gene synonyms
NCBI Gene ID
1719
Protein name
dihydrofolate reductase
Protein synonyms
Uniprot ID
Q6IRW8
Mouse ortholog
Dhfr (13361)
dihydrofolate reductase (Q61579)
Alternate
TYMS
TYMS
SLC46A1
SLC46A1
GART
GART
Organism
Homo sapiens
Gene name
TYMS
Gene synonyms
TS
NCBI Gene ID
7298
Protein name
thymidylate synthase
Protein synonyms
TSase
Uniprot ID
Q8WYK4
Mouse ortholog
Tyms (22171)
thymidylate synthase (P07607)
Variants
Clinical Variant
No data
Financial
Alimta - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Pemfexy - Eagle Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 19,012 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
30,538 adverse events reported
View more details